Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Glenmark’s Favipiravir successful in treating patients with mild COVID-19 symptoms

PTI
Updated: July 22nd, 2020, 19:26 IST
in Coronavirus, National, Top Stories
0
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

New Delhi:  Glenmark Pharmaceuticals said Wedensday that the Phase 3 clinical trial of antiviral drug Favipiravir is giving hope. Glenmark Pharmaceuticals said Favipiravir is helping mild to moderate COVID-19 patients get clinical improvement in ‘significantly faster time’.

Results from the Phase 3 trial showed numerical improvements for the primary efficacy endpoint with 28.6 per cent faster viral clearance in the overall population in the ‘Favipiravir’ plus standard supportive care compared to those in the standard supportive care alone (control arm) , Glenmark said in a statement.

Also Read

Representational image
(Pic- IANS)

Delhi women allege harassment by youths in Odisha’s Jajpur

9 hours ago
An Aeroplane approaches the landing strip at Biju Patnaik International Airport under an overcast sky in Bhubaneswar Thursday

Airspace ban on Pakistan airlines extended till July 24: India

9 hours ago

The results also demonstrated 40 per cent faster achievement of ‘clinical cure’ defined as the physician’s assessment of normalisation of clinical signs – temperature, oxygen saturation, respiratory rate and cough, the statement added.

“It should be stated that 69.8 per cent of patients in the Favipiravir plus standard supportive care (Favipiravir treatment arm) achieved clinical cure by Day 4, which was statistically significant compared to 44.9 per cent observed in the control arm,” the statement said.

Among patients who clinically deteriorated and required oxygen support, those receiving Favipiravir had a longer median time to first time use of oxygen of five days versus two days in the control arm, the company added.

‘Favipiravir’ was well tolerated with no serious adverse events or deaths. Adverse events were reported in 26 patients in the Favipiravir treatment arm as compared to six patients in the control arm, it added.

However, most adverse events were mild to moderate and none led to drug discontinuation or dosing adjustments, the statement said.

“We are encouraged with the top-line results and these indicate that early treatment with Favipiravir may improve clinical outcomes for mild to moderate patients and could potentially prevent patients from progressing to ARDS and mortality,” Glenmark Vice-President & Head – Clinical Development, Global Specialty/Branded Portfolio Monika Tandon said.

The company had announced June 20 the receiving, manufacturing and marketing approval from India’s drug regulator for Favipiravir for the treatment of mild to moderate COVID-19. The  company sells the drug under the brand name ‘FabiFlu’ at a price of Rs 75 per tablet.

Shares of Glenmark Pharmaceuticals settled at Rs 413.70 per scrip on BSE, down 0.13 per cent from its previous close.

PTI

 

Tags: COVID-19CureFabiFluFavipiravirGlenmarktreatment
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Priyabrata Mohanty

December 12, 2019
#MyPaperBagChallenge

Tabish Maaz

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Ipsita

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

Bijswajit Pradhan

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
#MyPaperBagChallenge

Dibya Ranjan Das

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Lopali Pattnaik

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Sarfraz Ahmad

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Narendra Kumar

December 12, 2019
#MyPaperBagChallenge

Matrumangal Jena

December 12, 2019
#MyPaperBagChallenge

Archana Parida

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Sibarama Khotei

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Mrutyunjaya Behera

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019
#MyPaperBagChallenge

Ankita Balabantray

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019

Archives

Editorial

Unending War

US-Iran
June 23, 2025

Last week, when a reporter asked US President Donald Trump whether America would enter the war on Iran with close...

Read more

Shouldering Arms

June 22, 2025

India has taken it as its responsibility to bring the Voice of the Global South (henceforth VoGS) to the world...

Read more

Quiet Scramble

June 21, 2025

The Modi government has recently relaxed its rules for selecting joint secretaries to encourage more IAS officers to take on...

Read more

Trouble For Iran

Iran flag
June 18, 2025

The escalating conflict between Israel and Iran has plunged the Middle East into deeper turmoil, with ramifications stretching far beyond...

Read more
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2024 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2024 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2024 All rights Reserved by OrissaPOST